

The REPAIR Impact Fund -


how it works



Each year, more than 700,000 people die from infections resistant to antibiotics. By 2050, this number could increase to 10 million – exceeding the current death toll from cancer.




The pharmaceutical value chain has an early-stage funding gap, from lead optimization up to Phase 1 data, since the lack of clinical evidence makes attracting capital difficult.



The REPAIR Impact Fund will invest USD 20–40 million per year over 3–5 years in about 20 projects involved in discovery and the early-stage development of therapies to combat antimicrobial resistance.

2.



Financial challenges have made developing new treatments for infections unattractive.

4.



The REPAIR Impact Fund has a budget of USD 165 million to address the funding gap and scientific expertise to identify the best projects to support.

6.



We expect the investments to yield at least one new therapy reaching the market. This will save hundreds of thousands if not millions of lives.

